{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=27",
    "query": {
      "intervention": "CTRL",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 26651,
    "total_pages": 2666,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T10:14:30.545Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04766086",
      "title": "Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Group B Streptococcus Infections"
      ],
      "interventions": [
        {
          "name": "Multivalent Group B streptococcus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus, diphtheria, and acellular pertussis vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 306,
      "start_date": "2022-08-12",
      "completion_date": "2023-04-27",
      "has_results": true,
      "last_update_posted_date": "2024-05-24",
      "last_synced_at": "2026-11-07T10:14:30.545Z",
      "location_count": 12,
      "location_summary": "Newton, Kansas • Omaha, Nebraska • Las Vegas, Nevada + 8 more",
      "locations": [
        {
          "city": "Newton",
          "state": "Kansas"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04766086"
    },
    {
      "nct_id": "NCT02281773",
      "title": "A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "BI 409306 100 mg QD",
          "type": "DRUG"
        },
        {
          "name": "BI 498306 50 mg QD",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "BI 498306 25 mg QD",
          "type": "DRUG"
        },
        {
          "name": "BI 409306 10 mg QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 518,
      "start_date": "2014-11-10",
      "completion_date": "2016-06-13",
      "has_results": true,
      "last_update_posted_date": "2017-10-19",
      "last_synced_at": "2026-11-07T10:14:30.545Z",
      "location_count": 24,
      "location_summary": "Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 18 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02281773"
    },
    {
      "nct_id": "NCT00121069",
      "title": "Study of Escitalopram in the Treatment of Specific Phobia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Phobic Disorders"
      ],
      "interventions": [
        {
          "name": "Escitalopram",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Connor, Kathryn M., M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2002-09",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2005-07-21",
      "last_synced_at": "2026-11-07T10:14:30.545Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00121069"
    },
    {
      "nct_id": "NCT04662073",
      "title": "COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Camostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 2,
      "start_date": "2021-04-23",
      "completion_date": "2022-03-04",
      "has_results": true,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-11-07T10:14:30.545Z",
      "location_count": 2,
      "location_summary": "Pleasanton, California • Stanford, California",
      "locations": [
        {
          "city": "Pleasanton",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04662073"
    },
    {
      "nct_id": "NCT07117669",
      "title": "Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "ENP-501",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "N-Fold, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "14 Years to 50 Years"
      },
      "enrollment_count": 68,
      "start_date": "2025-12-16",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-11-07T10:14:30.545Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07117669"
    },
    {
      "nct_id": "NCT01593683",
      "title": "Waitlist-controlled Trial of a Psychological Education Program for Nurses",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Psychological Stress"
      ],
      "interventions": [
        {
          "name": "Psychological education program for nurses",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2012-03",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2013-07-10",
      "last_synced_at": "2026-11-07T10:14:30.545Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01593683"
    },
    {
      "nct_id": "NCT04795466",
      "title": "Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment",
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "45 Years to 90 Years"
      },
      "enrollment_count": 34,
      "start_date": "2021-10-28",
      "completion_date": "2024-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-11-07T10:14:30.545Z",
      "location_count": 2,
      "location_summary": "Charlestown, Massachusetts • Stony Brook, New York",
      "locations": [
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04795466"
    },
    {
      "nct_id": "NCT06095102",
      "title": "A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "JNJ-77242113",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 311,
      "start_date": "2023-10-12",
      "completion_date": "2027-02-17",
      "has_results": true,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-07T10:14:30.545Z",
      "location_count": 28,
      "location_summary": "Scottsdale, Arizona • Fort Smith, Arkansas • Encinitas, California + 24 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Alpharetta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06095102"
    },
    {
      "nct_id": "NCT05355402",
      "title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertriglyceridemia",
        "Atherosclerotic Cardiovascular Disease",
        "Severe Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Olezarsen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 154,
      "start_date": "2022-05-09",
      "completion_date": "2023-12-21",
      "has_results": true,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-11-07T10:14:30.545Z",
      "location_count": 21,
      "location_summary": "Lincoln, California • Montclair, California • Boca Raton, Florida + 17 more",
      "locations": [
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05355402"
    },
    {
      "nct_id": "NCT00077753",
      "title": "EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "enoxaparin sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 4726,
      "start_date": "2002-02",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2011-01-11",
      "last_synced_at": "2026-11-07T10:14:30.545Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00077753"
    }
  ]
}